Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020

バイオシミュレーションの世界市場

◆タイトル:Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020
◆商品コード:MAM-HIT-3629
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年7月30日
◆ページ数:149
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:IT
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、バイオシミュレーションの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、製品別分析、用途別分析、需要先別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。

The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:
• Product Development: Product portfolios of the top players in the biosimulation market.
• Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Stakeholders

2 Research Methodology (Page No. – 17)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.3.3 Assumptions for the Study

3 Executive Summary (Page No. – 24)

4 Premium Insights (Page No. – 28)
4.1 Lucrative Opportunities in the Global Biosimulation Market
4.2 Life Cycle Analysis, By Region (2015–2020)

5 Market Overview (Page No. – 32)
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Product
5.2.2 By Application
5.2.3 By End User
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Growth in the Pharmaceutical and Biotechnology Industries
5.3.1.2 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries
5.3.1.3 Technological Advancements
5.3.1.4 Need to Curtail Drug Discovery and Development Costs
5.3.1.5 Growth in the Biologics and Biosimilars Market and Increased Use of Personalized Medicines
5.3.2 Restraints
5.3.2.1 Lack of Standardization
5.3.2.2 Lack of Trained Professionals
5.3.3 Opportunities
5.3.3.1 Emerging Applications
5.3.4 Challenges
5.3.4.1 Limited Knowledge of Biological Systems and Processes
5.3.5 Trends
5.3.5.1 Collaborations of Universities and Research Labs With Suppliers

6 Biosimulation Market, By Product (Page No. – 42)
6.1 Introduction
6.2 Software
6.2.1 PK/PD Modeling and Simulation Software
6.2.2 Molecular Modeling and Simulation Software
6.2.3 Pbpk Modeling and Simulation Software
6.2.4 Toxicity Prediction Software
6.2.5 Trial Design Software
6.2.6 Other Software
6.3 Services
6.3.1 In-House Services
6.3.2 External/Contract Services

7 Biosimulation Market, By Application (Page No. – 55)
7.1 Introduction
7.2 Drug Development
7.2.1 Preclinical Testing
7.2.1.1 PK/PD
7.2.1.2 ADME/TOX
7.2.2 Clinical Trials
7.3 Drug Discovery
7.3.1 Target Identification and Validation
7.3.2 Lead Identification and Optimization
7.4 Other Applications

8 Biosimulation Market, By End User (Page No. – 70)
8.1 Introduction
8.2 Pharmaceutical and Biotechnology Companies
8.3 Academic and Government Research Institutes
8.4 Contract Research Organizations
8.5 Regulatory Authorities
8.6 Other End Users

9 Global Biosimulation Market, By Region (Page No. – 81)
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia
9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. – 108)
10.1 Introduction
10.2 Strategic Overview
10.3 Leading Players in the Biosimulation Market
10.4 Competitive Situation and Trends
10.4.1 Product Upgradation
10.4.2 Agreements, Collaborations, Expansions, and Partnerships
10.4.3 New Product and Service Launches
10.4.4 Acquisitions
10.4.5 Other Developments

11 Company Profiles (Page No. – 116)
11.1 Introduction
11.2 Certara USA, Inc.
11.2.1 Business Overview
11.2.2 Products Offered
11.2.3 Recent Developments
11.2.4 MnM View
11.3 Simulation Plus Inc.
11.3.1 Business Overview
11.3.2 Products Offered
11.3.3 Recent Developments
11.3.4 MnM View
11.4 Dassault Systèmes SA
11.4.1 Business Overview
11.4.2 Products Offered
11.4.3 Recent Developments
11.4.4 MnM View
11.5 Schrödinger Inc.
11.5.1 Business Overview
11.5.2 Products Offered
11.5.3 Recent Developments
11.5.4 MnM View
11.6 Advanced Chemistry Development, Inc.
11.6.1 Business Overview
11.6.2 Products Offered
11.6.3 Recent Developments
11.6.4 MnM View
11.7 Chemical Computing Group, Inc.
11.7.1 Business Overview
11.7.2 Products Offered
11.7.3 Recent Developments
11.7.4 MnM View
11.8 Entelos Holding Corporation
11.8.1 Business Overview
11.8.2 Products Offered
11.8.3 Recent Developments
11.8.4 MnM View
11.9 Genedata Ag
11.9.1 Business Overview
11.9.2 Products Offered
11.9.3 Recent Developments
11.9.4 MnM View
11.10 Physiomics PLC
11.10.1 Business Overview
11.10.2 Products Offered
11.10.3 Recent Developments
11.10.4 MnM View
11.11 Rhenovia Pharma Ltd.
11.11.1 Business Overview
11.11.2 Products Offered
11.11.3 Recent Developments
11.11.4 MnM View

12 Appendix (Page No. – 135)
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Other Developments
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports

List of Tables (75 Tables)

Table 1 Market Summary of Biosimulation
Table 2 Growth in the Pharmaceutical and Biotechnology Industries Along With Increase in R&D Investments in These Industries is Propelling the Growth of the Biosimulation Market
Table 3 Lack of Standardization to Restrict Market Growth of Biosimulation
Table 4 Emerging Applications Present Significant Growth Opportunities for the Biosimulation Market
Table 5 Limited Knowledge of Biological Systems and Processes Pose A Challenge for the Biosimulation Market
Table 6 Collaborations of Universities and Research Labs With Suppliers is A Major Trend Observed in This Market
Table 7 Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 8 Biosimulation Software Market Size, By Type, 2013–2020 (USD Million)
Table 9 Biosimulation Software Market Size, By Region, 2013–2020 (USD Million)
Table 10 Biosimulation Market Size for PK/PD Modeling and Simulation Software, By Region, 2013–2020 (USD Million)
Table 11 Biosimulation Market Size for Molecular Modeling and Simulation Software, By Region, 2013–2020 (USD Million
Table 12 Biosimulation Market Size for Pbpk Modeling and Simulation Software, By Region, 2013–2020 (USD Million)
Table 13 Biosimulation Market Size for Toxicity Prediction Software, By Region, 2013–2020 (USD Million)
Table 14 Biosimulation Market Size for Trial Design Software, By Region, 2013–2020 (USD Million)
Table 15 Biosimulation Market Size for Other Software, By Region, 2013–2020 (USD Million)
Table 16 Biosimulation Services Market Size, By Type, 2013–2020 (USD Million)
Table 17 Biosimulation Services Market Size, By Region, 2013–2020 (USD Million)
Table 18 Biosimulation Market Size for In-House Services, By Region, 2013–2020 (USD Million)
Table 19 Biosimulation Market Size for External/Contract Services, By Region, 2013–2020 (USD Million)
Table 20 Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 21 Market Size for Biosimulation Drug Development, By Application, 2013–2020 (USD Million )
Table 22 Market Size for Biosimulation Drug Development, By Region, 2013–2020 (USD Million)
Table 23 Market Size for Preclinical Testing, By Application, 2013–2020 (USD Million )
Table 24 Biosimulation Market Size for Preclinical Testing, By Region, 2013–2020 (USD Million )
Table 25 Market Size for PK/PD, By Region, 2013–2020 (USD Million)
Table 26 Market Size for ADME/TOX, By Region, 2013–2020 (USD Million)
Table 27 Biosimulation Market Size for Clinical Trials, By Region, 2013–2020 (USD Million)
Table 28 Market Size for Biosimulation Drug Discovery, By Application, 2013–2020 (USD Million )
Table 29 Biosimulation Market Size for Biosimulation Drug Discovery, By Region, 2013–2020 (USD Million )
Table 30 Market Size for Target Identification and Optimization, By Region, 2013–2020 (USD Million)
Table 31 Market Size for Lead Identification and Optimization, By Region, 2013–2020 (USD Million)
Table 32 Biosimulation Market Size for Other Applications, By Region, 2013–2020 (USD Million )
Table 33 Market Size, By End User, 2013–2020 (USD Million)
Table 34 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2013–2020 (USD Million)
Table 35 Market Size for Academic and Government Research Institutes, By Region, 2013–2020 (USD Million)
Table 36 Biosimulation Market Size for Cros, By Region, 2013–2020 (USD Million)
Table 37 Biosimulation Market Size for Regulatory Authorities, By Region, 2013–2020 (USD Million)
Table 38 Biosimulation Market Size for Other End Users, By Region, 2013–2020 (USD Million)
Table 39 Biosimulation Market Size, By Region, 2013–2020 (USD Million)
Table 40 North America: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 41 North America: Biosimulation Market Size, By Software, 2013–2020 (USD Million)
Table 42 North America: Market Size, By Service, 2013–2020 (USD Million)
Table 43 North America: Market Size, By Application, 2013–2020 (USD Million)
Table 44 North America: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 45 North America: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 46 North America: Biosimulation Market Size, By End User, 2013–2020 (USD Million)
Table 47 Europe: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 48 Europe: Market Size, By Software, 2013–2020 (USD Million)
Table 49 Europe: Biosimulation Market Size, By Service, 2013–2020 (USD Million)
Table 50 Europe: Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 51 Europe: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 52 Europe: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 53 Europe: Biosimulation Market Size, By End User, 2013–2020 (USD Million)
Table 54 Asia: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 55 Asia: Market Size, By Software, 2013–2020 (USD Million)
Table 56 Asia: Market Size, By Service, 2013–2020 (USD Million)
Table 57 Asia: Market Size, By Application, 2013–2020 (USD Million)
Table 58 Asia: Biosimulation Market Size for Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 59 Asia: Biosimulation Market Size for Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 60 Asia: Market Size, By End User, 2013–2020 (USD Million)
Table 61 RoW: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 62 RoW: Biosimulation Market Size, By Software, 2013–2020 (USD Million)
Table 63 RoW: Market Size, By Service, 2013–2020 (USD Million)
Table 64 RoW: Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 65 RoW: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 66 RoW: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 67 RoW: Market Size, By End User, 2013–2020 (USD Million)
Table 68 Rank of Companies in the Global Market, 2015
Table 69 Market Developments of Biosimulation Between 2013 and 2015
Table 70 Product Upgradation, 2013–2015
Table 71 Agreements, Collaborations, Expansions, and Partnerships, 2013–2015
Table 72 New Product and Service Launches, 2013–2015
Table 73 Acquisitions, 2013–2015
Table 74 Other Developments, 2013–2015
Table 75 Strategic Benchmarking of Market Players of Biosimulation

List of Figures (64 Figures)

Figure 1 Global Biosimulation Market
Figure 2 Research Methodology
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Biosimulation Market Size, By Product, 2015 vs 2020 (USD Million)
Figure 8 Biosimulation Market Size, By Application, 2015 vs 2020 (USD Million)
Figure 9 Biosimulation Market Size, By End User, 2015 vs 2020 (USD Million)
Figure 10 Biosimulation Market Size, By Region, 2015 vs 2020 (USD Million)
Figure 11 Global Biosimulation Market to Witness High Growth During the Forecast Period
Figure 12 Biosimulation Software Product Segment to Account for the Largest Market Share in 2015
Figure 13 Europe to Witness Highest Growth Rate From 2015 to 2020
Figure 14 European Market Showcases Lucrative Growth Opportunities of Biosimulation
Figure 15 Biosimulation Market Segmentation: By Product
Figure 16 Biosimulation Market Segmentation: By Application
Figure 17 Biosimulation Market Segmentation: By End User
Figure 18 Growth in the Pharmaceutical and Biotechnology Industries Along With Increase in R&D Investments in These Industries Will Drive the Biosimulation Market
Figure 19 New Pharmaceutical Drug Launches (2003–2013)
Figure 20 Biosimulation Market Segmentation, By Product
Figure 21 Biosimulation Market, By Product, 2015 (USD Million)
Figure 22 Biosimulation Software Market Size, By Type, 2015 vs 2020 (USD Million)
Figure 23 Biosimulation Software Market Size, By Region, 2015 vs 2020 (USD Million)
Figure 24 Biosimulation Services Market Size, By Type, 2013–2020 (USD Million)
Figure 25 Biosimulation Services Market Size, By Region, 2013–2020 (USD Million)
Figure 26 Biosimulation Market Segmentation, By Application
Figure 27 Drug Development Segment to Command the Largest Share of the Biosimulation Market in 2015
Figure 28 Biosimulation Market Size for Drug Development, By Application, 2015 vs 2020 (USD Million )
Figure 29 North America Expected to Be the Largest Regional Segment for Drug Development Applications
Figure 30 Biosimulation Market Size for Preclinical Testing, By Application, 2015 vs 2020 (USD Million)
Figure 31 North America Expected to Be the Largest Regional Segment for Preclinical Testing Applications
Figure 32 Biosimulation Market Size for Drug Discovery, By Application, 2015 vs 2020 (USD Million )
Figure 33 Europe is the Fastest-Growing Regional Segment for Drug Discovery Applications
Figure 34 Other Applications Market in Europe to Witness Highest Growth in the Forecast Period
Figure 35 Biosimulation Market, By End User
Figure 36 Biosimulation Market Size, By End User, 2015 (USD Million)
Figure 37 Number of Biotechnology and Pharmaceutical Patents Granted in 2012, By Region
Figure 38 Pharmaceutical and Biotechnology Companies Segment to Witness Highest Growth in Europe
Figure 39 Public-Sector Research Funding Driving the Growth of the Academic & Government Research Institutes End-User Segment
Figure 40 North America Dominates Market for Academic and Government Research Institutes
Figure 41 North America Expected to Dominate Biosimulation Market for Cros
Figure 42 Europe is Expected to Grow at the Highest Cagr in the Biosimulation Market for Regulatory Authorities
Figure 43 Europe to Witness Highest Growth in the Biosimulation Market for Other End Users in the Forecast Period
Figure 44 Biosimulation Market Segmentation, By Region
Figure 45 North America to Dominate the Global Biosimulation Market in the Forecast Period
Figure 46 Biosimulation Market in Europe to Witness the Highest Growth From 2015 to 2020
Figure 47 North America: Market Snapshot
Figure 48 Biosimulation Software to Command the Largest Share of the Biosimulation Market in North America in 2015
Figure 49 Drug Development Segment to Account for the Largest Share of the Biosimulation Applications Market in North America By 2020
Figure 50 Pharmaceutical and Biotechnology Companies to Form the Largest End-User Segment in North America in 2015
Figure 51 Europe: Market Snapshot
Figure 52 Biosimulation Software to Command the Largest Share of the European Biosimulation Market in 2015
Figure 53 Drug Development Segment to Account for the Largest Share of the Biosimulation Applications Market in Europe By 2020
Figure 54 Pharmaceutical and Biotechnology Companies to Account for the Largest Share of the Biosimulation End-User Market in Europe in 2015
Figure 55 Biosimulation Software to Command the Largest Share of the Biosimulation Market in Asia in 2015
Figure 56 Drug Development Application Segment to Dominate the Biosimulation Market in Asia By 2020
Figure 57 Pharmaceutical and Biotechnology Companies to Account for the Largest Share of the Biosimulation End-User Market in Asia in 2015
Figure 58 Biosimulation Software to Command the Largest Share of the RoW Biosimulation Market in 2015
Figure 59 Drug Development Application Segment to Command the Largest Share of the Biosimulation Market in the RoW Region By 2020
Figure 60 Pharmaceutical and Biotechnology Companies End-User Segment to Dominate the RoW Market for Biosimulation in 2015
Figure 61 Key Developments in the Biosimulation Market, 2013-2015
Figure 62 Company Snapshot: Simulation Plus Inc.
Figure 63 Company Snapshot: Dassault Systèmes SA
Figure 64 Company Snapshot: Physiomics PLC

【レポートのキーワード】

バイオシミュレーション、ソフトウェア、分子モデリング、PK/PDモデリング、PKPDモデリング、毒性予測ソフトウェア、バイオシミュレーションサービス、バイオシミュレーション用途

★調査レポート[バイオシミュレーションの世界市場] ( Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 / MAM-HIT-3629) 販売に関する免責事項
[バイオシミュレーションの世界市場] ( Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 / MAM-HIT-3629) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆